{"data":{"id":1137,"lang":"en","title":"Penn Scientists Develop Gene Therapy That Relieves Pain Without Opioid Addiction Risk","summary":"Penn researchers publish first brain-targeted gene therapy for pain in Nature, offering opioid-level relief without addiction risk.","category":"science","category_label":"Science","published_at":"2026-03-29T17:01:46Z","updated_at":"2026-03-29T17:01:46Z","url":"https://techtools.cz/tools/news/article/1137-penn-scientists-develop-gene-therapy-that-relieves-pain-without-opioid","api_url":"https://techtools.cz/news-api/v1/articles/1137?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/1137.md?lang=en","image_url":"https://tupa-q-001.sitecorecontenthub.cloud/api/public/content/85fe170e401f428f9391ff6f081847b2?v=1ff843c0","word_count":157,"reading_time_minutes":1,"sources":[{"url":"https://www.nature.com/articles/s41586-025-09908-w","domain":"nature.com"},{"url":"https://www.pennmedicine.org/news/gene-therapy-switch-may-offer-non-addictive-pain-relief","domain":"pennmedicine.org"},{"url":"https://www.sciencedaily.com/releases/2026/03/260328043558.htm","domain":"sciencedaily.com"}],"translation":{"lang":"cs","id":1184,"title":"Vědci z Pensylvánie vyvinuli genovou terapii, která tišì bolest bez rizika závislosti na opioidech","url":"https://techtools.cz/tools/news/clanek/1184-vedci-z-pensylvanie-vyvinuli-genovou-terapii-ktera-tisi-bolest-bez-rizika","api_url":"https://techtools.cz/news-api/v1/articles/1184?lang=cs"},"content":"Researchers at the University of Pennsylvania have created a gene therapy that acts as a precise \"off switch\" for chronic pain in the brain, without triggering the addictive reward pathways that make opioids so dangerous. Published in Nature on March 28, the therapy uses AI-driven behavioral tracking to map how pain is processed in cortical circuits, then delivers a targeted intervention that mimics morphine's analgesic benefits while skipping its side effects.\n\nLead researcher Gregory Corder, assistant professor of psychiatry and neuroscience at Penn, called it \"the world's first CNS-targeted gene therapy for pain and a concrete blueprint for non-addictive, circuit-specific pain medicine.\" The six-year project, funded by an NIH New Innovator Award, involved collaborators from Carnegie Mellon University and Stanford University.\n\nThe breakthrough addresses a massive public health crisis: over 50 million Americans live with chronic pain, costing more than $635 billion annually, while opioids were involved in 80% of 600,000 drug-related deaths in 2019 alone."}}